ArticleInfection and immunity2018
Comparative Analysis of the Capacity of the
Article in Infection and immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- An In Vitro A-431 Epithelial Cell Infection Model for Studying Fungal Pathogenicity and Immune Responses Associated With Vulvovaginal Candidiasis.Bio-protocol · 2026Article
- Perspectives on Vaginal Ecology and Management of Recurrent Vulvovaginal Candidiasis: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Article
- Probiotic Lactobacillus Species Modulate Immune Responses During Vaginal Epithelial Cell Colonization.The Journal of infectious diseases · 2025Article
- Insights into the evolution of Candidalysin and recent developments.Archives of microbiology · 2025Review
- Vaginal mycobiome characteristics and therapeutic strategies in vulvovaginal candidiasis (VVC): differentiating pathogenic species and microecological features for stratified treatment.Clinical microbiology reviews · 2025Review
- Myricetin Exerts Antibiofilm Effects onJournal of fungi (Basel, Switzerland) · 2025Article
- New insights toward personalized therapies for vulvovaginal candidiasis and vaginal co-infections.Frontiers in microbiology · 2025Review
- Molecular mechanisms of neutrophil regulatory network in anti-Candida infection.Frontiers in immunology · 2025Review
- Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.Cell host & microbe · 2024Review
- Vulvovaginal candidiasis culture results from a major national commercial laboratory, United States, 2019-2023.American journal of obstetrics and gynecology · 2024Article
- Vertebrate and invertebrate animal infection models of Candida auris pathogenicity.Current opinion in microbiology · 2024Review
- Innate immune response to Candida auris.Current opinion in microbiology · 2024Review
- SWI/SNF complex-mediated chromatin remodeling iniScience · 2024Article
- Article
- Impaired neutrophil extracellular trap-forming capacity contributes to susceptibility to chronic vaginitis in a mouse model of vulvovaginal candidiasis.Infection and immunity · 2024Article
- Inflammatory cytokine signalling in vulvovaginal candidiasis: a hot mess driving immunopathology.Oxford open immunology · 2024Review
- The Interplay betweenMicroorganisms · 2023Review
- A New Phenotype inmBio · 2023Article
- Pathogenesis and virulence ofVirulence · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The human fungal pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.